Roche to Acquire Outstanding Shares of Foundation Medicine for $2.4B

Jun 19, 2018

|

NEW YORK (GenomeWeb) – Roche will acquire the remainder of Foundation Medicine for $2.4 billion in cash, the companies said today.

Roche already owned about 57 percent of Foundation's outstanding common stock, following a tender offer in 2015.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Scan

And Deal

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

For Long Life

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

Positive Review

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

This Week in Nucleic Acids Research

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.

Featured White Papers

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

DNA Quantification and Normalization with Promega QuantiFluor Dyes on the Fluent Laboratory Automation Solution

Nucleic Acid Quantification and Normalization by UV Measurement on the Fluent Laboratory Automation Solution

qPCR Setup with the Kapa SYBR FAST qPCR Kit on the Fluent Automation Workstation

Jan

30

Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS Approaches for Microbiome Studies

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Main menu